Wave Life Sciences has pioneered manufacturing of precise (stereopure) RNAi and other oligonucleotides. Foresite Capital believes that RNAi and oligonucleotide therapies that are in development provide demonstration that a variety of genetic diseases can be treated. However, the current RNAi and oligonucleotide drugs in development are all racemic mixtures, which often have millions of stereopure components that vastly vary in their activity. Wave can identify the most active stereopure element of the mixture, patent the composition of matter, and manufacture at scale a stereopure component which is the most potent and specific member of the mixture. This enables Wave to compete in all areas of nucleotide treatments with more potent and specific patented constructs. Wave is focusing first on rare genetic disorders where oligonucleotides mixtures have demonstrated the ability to correct the underlying genetic defect, such as Duchene’s Muscular Dystrophy and Huntington’s Chorea but are not potent enough because of the large number of low active members of the racemic mixture.